Patricia Ribaud
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Patricia Ribaud has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
A Devergie
Stem cell Transplant Unit, Saint Louis Hospital, Paris, France
9 shared publications- Gérard Socié
Department of Hematology-BMT, Hopital Saint Louis, Paris, France
7 shared publications - Eliane Gluckman
Hôpital Saint Louis, Paris, France
6 shared publications Eliane Gluckman
Service des Maladies Infectieuses et Tropicales,1 Laboratoire de Parasitologie-Mycologie,2 Service d'Hématologie-Greffe de Moelle,4 Service de Pneumologie, Hôpital Saint-Louis,5 Centre National de Référence Mycologie et Antifongiques, Unité de Mycologie Moléculaire, CNRS FRE2849, Institut Pasteur, Paris, France3
5 shared publications- Eliane Gluckman
Bone Marrow Transplant Unit, Hospital Saint-Louis, Paris, France
5 shared publications R Traineau
Stem cell Transplant Unit, Saint Louis Hospital, Paris, France
5 shared publications
Latest Publications
- 1 January 2015
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 32, A169
Aspergilloses pulmonaires invasives survenant sous traitement par posaconazole (PZA)
- 1 January 2015
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 32, A169
Aspergilloses pulmonaires invasives survenant sous traitement par posaconazole (PZA)
- Open Access
- 1 September 2005
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 43 (9) , 4902-4904
Breakthrough Disseminated Aspergillus ustus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients Receiving Voriconazole or Caspofungin Prophylaxis
Aspergillus ustus is an uncommon clinical species which is poorly susceptible to antifungals. We report two cases of A. ustus infections that occurred in allogeneic stem cell transplant recipients while they were receiving either voriconazole or caspofungin. Prolonged use of these new antifungal agents may increase the risk of the emergence of resistant organisms.
- 1 September 2005
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 43 (9) , 4902-4904
Open AccessBreakthrough Disseminated Aspergillus ustus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients Receiving Voriconazole or Caspofungin Prophylaxis
Aspergillus ustus is an uncommon clinical species which is poorly susceptible to antifungals. We report two cases of A. ustus infections that occurred in allogeneic stem cell transplant recipients while they were receiving either voriconazole or caspofungin. Prolonged use of these new antifungal agents may increase the risk of the emergence of resistant organisms.
- Open Access
- 1 April 2002
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 34 (7) , 939-943
Invasive Aspergillosis in Allogeneic Stem Cell Transplant Recipients: Increasing Antigenemia Is Associated with Progressive Disease
The kinetics of serum Aspergillus galactomannan, as determined by enzyme-linked immunosorbent assay, was examined in 37 allogeneic stem cell transpla
- 1 April 2002
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 34 (7) , 939-943
Open AccessInvasive Aspergillosis in Allogeneic Stem Cell Transplant Recipients: Increasing Antigenemia Is Associated with Progressive Disease
The kinetics of serum Aspergillus galactomannan, as determined by enzyme-linked immunosorbent assay, was examined in 37 allogeneic stem cell transpla
- 1 March 2001
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 27 (6) , 575-580
Influence of CD34+ marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia
In order to study the influence of bone marrow CD34+ cell dose on the outcome of allogeneic bone marrow transplantation (BMT), we analysed the results of BMT from HLA-identical siblings donors in 50 patients with chronic myeloid leukaemia (CML). The median numbers of nucleated cells (NC) and CD34+ cells infused were 2.18 × 108/kg (0.05–4.14 × 108/kg) and 3.12 × 106/kg (0.35–8.52 × 106/kg), respectively. All patients engrafted. In univariate analysis, there was no correlation between the number of CD34+ cells infused and the time to neutrophil recovery (P = 0.17). The Kaplan–Meier estimate of grade II–IV acute graft-versus-host disease (GVHD) at day 100 was 53 ± 14% and 2-year survival was 46 ± 15%. A number of CD34+ cells infused greater than the median was the main factor increasing survival (P = 0.0006) and decreasing 100 day transplant-related mortality (P = 0.009). Patient-, disease- and transplant-related characteristics were not statistically different among patients receiving more or less than the median number of CD34+ cells. The rate of infectious deaths was significantly higher in patients receiving less than 3.12 × 106 CD34/kg (48% vs 16%, P = 0.01). In a multivariable analysis, two factors associated with increased risk of death were advanced disease status at transplant (HR: 2.5 (95% CI: 1.09–5.75), P = 0.03) and a lower number of marrow CD34+ cells infused/kg (HR: 4.55 (95% CI: 1.87–10.90), P = 0.0008). Bone Marrow Transplantation (2001) 27, 575–580.
- 1 March 2001
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 27 (6) , 575-580
Influence of CD34+ marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia
In order to study the influence of bone marrow CD34+ cell dose on the outcome of allogeneic bone marrow transplantation (BMT), we analysed the results of BMT from HLA-identical siblings donors in 50 patients with chronic myeloid leukaemia (CML). The median numbers of nucleated cells (NC) and CD34+ cells infused were 2.18 × 108/kg (0.05–4.14 × 108/kg) and 3.12 × 106/kg (0.35–8.52 × 106/kg), respectively. All patients engrafted. In univariate analysis, there was no correlation between the number of CD34+ cells infused and the time to neutrophil recovery (P = 0.17). The Kaplan–Meier estimate of grade II–IV acute graft-versus-host disease (GVHD) at day 100 was 53 ± 14% and 2-year survival was 46 ± 15%. A number of CD34+ cells infused greater than the median was the main factor increasing survival (P = 0.0006) and decreasing 100 day transplant-related mortality (P = 0.009). Patient-, disease- and transplant-related characteristics were not statistically different among patients receiving more or less than the median number of CD34+ cells. The rate of infectious deaths was significantly higher in patients receiving less than 3.12 × 106 CD34/kg (48% vs 16%, P = 0.01). In a multivariable analysis, two factors associated with increased risk of death were advanced disease status at transplant (HR: 2.5 (95% CI: 1.09–5.75), P = 0.03) and a lower number of marrow CD34+ cells infused/kg (HR: 4.55 (95% CI: 1.87–10.90), P = 0.0008). Bone Marrow Transplantation (2001) 27, 575–580.
- Open Access
- 1 October 2000
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 31 (4) , 927-935
Resistant Herpes Simplex Virus Type 1 Infection: An Emerging Concern after Allogeneic Stem Cell Transplantation
Fourteen cases of severe acyclovir-resistant herpes simplex virus type 1 (HSV-1) infection, 7 of which showed resistance to foscarnet, were diagnosed
- 1 October 2000
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 31 (4) , 927-935
Open AccessResistant Herpes Simplex Virus Type 1 Infection: An Emerging Concern after Allogeneic Stem Cell Transplantation
Fourteen cases of severe acyclovir-resistant herpes simplex virus type 1 (HSV-1) infection, 7 of which showed resistance to foscarnet, were diagnosed
- 1 November 1999
- Published by Wiley in Pediatric Transplantation
- Vol. 3, 41-44
Hepatic veno-occlusive disease
Hepatic veno-occlusive disease (VOD) after stem cell transplantation is a toxic manifestation of the conditioning regimen most probably emphasized by the allogeneic reaction. Its overall mortality rate is < 4% in adults as well as in children. Recent progress has been achieved in the diagnosis of this complication. However, better methods of both prophylaxis and treatment are needed.
- 1 November 1999
- Published by Wiley in Pediatric Transplantation
- Vol. 3, 41-44
Hepatic veno-occlusive disease
Hepatic veno-occlusive disease (VOD) after stem cell transplantation is a toxic manifestation of the conditioning regimen most probably emphasized by the allogeneic reaction. Its overall mortality rate is < 4% in adults as well as in children. Recent progress has been achieved in the diagnosis of this complication. However, better methods of both prophylaxis and treatment are needed.
- 18 September 1999
- Vol. 28 (27) , 1488-94
[Bone marrow transplantation in the treatment of autoimmune diseases. ISAMAIR Group].
EXPERIMENTAL BASIS AND CLINICAL OBSERVATIONS: Remission of an autoimmune disease has been observed in certain patients after bone marrow allograft from a healthy donor. Autoimmune disease in the donor can also be transmitted to an unaffected recipient. These phenomena would be hematopoietic-dependent. BONE MARROW ALLOGRAFTS: Indications for the treatment of refractory autoimmune diseases are exceptional due to the related mortality even in patients without malignant hematologic disease. A NEW THERAPEUTIC CONCEPT: Therapeutic intensification, followed with autologous peripheral stem cell grafts, a procedure with a mortality below 3% in 1997, constitutes a therapeutic alternative in these difficult indication concerning severe refractory autoimmune diseases including: sclerodermia, vasculitis, lupus, inflammatory myositis, autoimmune cyopenia.
- 18 September 1999
- Vol. 28 (27) , 1488-94
[Bone marrow transplantation in the treatment of autoimmune diseases. ISAMAIR Group].
EXPERIMENTAL BASIS AND CLINICAL OBSERVATIONS: Remission of an autoimmune disease has been observed in certain patients after bone marrow allograft from a healthy donor. Autoimmune disease in the donor can also be transmitted to an unaffected recipient. These phenomena would be hematopoietic-dependent. BONE MARROW ALLOGRAFTS: Indications for the treatment of refractory autoimmune diseases are exceptional due to the related mortality even in patients without malignant hematologic disease. A NEW THERAPEUTIC CONCEPT: Therapeutic intensification, followed with autologous peripheral stem cell grafts, a procedure with a mortality below 3% in 1997, constitutes a therapeutic alternative in these difficult indication concerning severe refractory autoimmune diseases including: sclerodermia, vasculitis, lupus, inflammatory myositis, autoimmune cyopenia.
- 1 May 1999
- Vol. 105 (2) , 366-8
Bone marrow transplantation for paroxysmal nocturnal haemoglobinuria.
Paroxysmal nocturnal haemoglobinuria (PNH) is an acquired clonal disorder of the haemopoietic stem cells for which the only curative treatment is bone marrow transplantation. There are few reports on the use of allogeneic transplantation for PNH, and nearly all of them include only a few patients. Between September 1978 and December 1997, 16 patients underwent marrow transplantation for PNH at the Hospital Saint Louis. The 5-year survival rate for the 16 patients was 58 +/- 13%. Two factors, an absolute neutrophil count >1.0 x 109/l and haemoglobin level >9 g/dl at transplant, were found to be statistically associated with a better outcome.
- 1 May 1999
- Vol. 105 (2) , 366-8
Bone marrow transplantation for paroxysmal nocturnal haemoglobinuria.
Paroxysmal nocturnal haemoglobinuria (PNH) is an acquired clonal disorder of the haemopoietic stem cells for which the only curative treatment is bone marrow transplantation. There are few reports on the use of allogeneic transplantation for PNH, and nearly all of them include only a few patients. Between September 1978 and December 1997, 16 patients underwent marrow transplantation for PNH at the Hospital Saint Louis. The 5-year survival rate for the 16 patients was 58 +/- 13%. Two factors, an absolute neutrophil count >1.0 x 109/l and haemoglobin level >9 g/dl at transplant, were found to be statistically associated with a better outcome.
- Open Access
- 1 February 1999
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 28 (2) , 322-330
Survival and Prognostic Factors of Invasive Aspergillosis After Allogeneic Bone Marrow Transplantation
To determine prognostic factors for survival in bone marrow transplant recipients with invasive aspergillosis (IA), we retrospectively reviewed 27 IA
- 1 February 1999
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 28 (2) , 322-330
Open AccessSurvival and Prognostic Factors of Invasive Aspergillosis After Allogeneic Bone Marrow Transplantation
To determine prognostic factors for survival in bone marrow transplant recipients with invasive aspergillosis (IA), we retrospectively reviewed 27 IA
- 1 January 1997
- Vol. 148 (2) , 132-5
[Veno-occlusive disease after bone marrow transplantation: preventive effect of heparin].
Liver veno-occlusive disease is a severe toxic effect observed after bone marrow transplantation. Clinical manifestations are jaundice, painful liver enlargement, and fluid-sodium retention. Histologically there is non-thrombotic obliteration of the centro-lobular veins associated with centro-lobular necrosis. This severe complication of bone marrow transplantation occurs early and is caused by a toxic processing effect. Incidence is variable, 2 to 50% in reported series, depending on patients, type of marrow provessing and on diagnostic criteria (which hinders comparison between studies). According to most studies, veno-occlusive disease regresses spontaneously. Mortality, depending on the severity of the symptoms, varies from 20 to 50%. Pathogenesis remains under debate: the initial event would occur in the sinusoid endothelium creating a state of local hypercoagulability by release of tissue factors favoring deposit of coagulation factors, especially factor VIII, in the subendothelial region of the veinules. There is also a direct toxic effect on centro-lobular hepatocytes which is further aggravated by ischemia and venous stasis. use of heparin to prevent veno-occlusive disease was proposed by the Besançon group in 1985 after they observed a low incidence (1 case in 65) in patients who were given low doses of heparin to maintain patent central catheters. The same team confirmed in 1992 the low incidence in a large retrospective series of 444 patients given either an autograft (3 cases in 253 patients, i.e. 1.2%), or an allograft (5 cases in 191 patients, i.e. 2.6%). Two single-center studies, one in Seattle and the other at the Saint-Antoine hospital in Paris, published in 1990 and 1991, did not show any difference in patients given heparin or not. Inversely, a randomized study published by Attal in 1992 including 161 patients showed a significant difference in the incidence of veno-occlusive disease between patients given heparin (2.5%) and those who were not given heparin (13.7%; p < 0.01). All these studies show that with low doses (100-150 U/kg) the risk is very very low. The mechanism of action of heparin would appear to be related to its protective effect on the endothelium rather than its hemostasis effect. The vascular protective effect of prostaglandin E1 suggests it might also be useful in preventing veno-occlusive disease.
- 1 January 1997
- Vol. 148 (2) , 132-5
[Veno-occlusive disease after bone marrow transplantation: preventive effect of heparin].
Liver veno-occlusive disease is a severe toxic effect observed after bone marrow transplantation. Clinical manifestations are jaundice, painful liver enlargement, and fluid-sodium retention. Histologically there is non-thrombotic obliteration of the centro-lobular veins associated with centro-lobular necrosis. This severe complication of bone marrow transplantation occurs early and is caused by a toxic processing effect. Incidence is variable, 2 to 50% in reported series, depending on patients, type of marrow provessing and on diagnostic criteria (which hinders comparison between studies). According to most studies, veno-occlusive disease regresses spontaneously. Mortality, depending on the severity of the symptoms, varies from 20 to 50%. Pathogenesis remains under debate: the initial event would occur in the sinusoid endothelium creating a state of local hypercoagulability by release of tissue factors favoring deposit of coagulation factors, especially factor VIII, in the subendothelial region of the veinules. There is also a direct toxic effect on centro-lobular hepatocytes which is further aggravated by ischemia and venous stasis. use of heparin to prevent veno-occlusive disease was proposed by the Besançon group in 1985 after they observed a low incidence (1 case in 65) in patients who were given low doses of heparin to maintain patent central catheters. The same team confirmed in 1992 the low incidence in a large retrospective series of 444 patients given either an autograft (3 cases in 253 patients, i.e. 1.2%), or an allograft (5 cases in 191 patients, i.e. 2.6%). Two single-center studies, one in Seattle and the other at the Saint-Antoine hospital in Paris, published in 1990 and 1991, did not show any difference in patients given heparin or not. Inversely, a randomized study published by Attal in 1992 including 161 patients showed a significant difference in the incidence of veno-occlusive disease between patients given heparin (2.5%) and those who were not given heparin (13.7%; p < 0.01). All these studies show that with low doses (100-150 U/kg) the risk is very very low. The mechanism of action of heparin would appear to be related to its protective effect on the endothelium rather than its hemostasis effect. The vascular protective effect of prostaglandin E1 suggests it might also be useful in preventing veno-occlusive disease.